Cargando…

The Longitudinal Analysis on the Anti-SARS-CoV-2 Antibodies among Healthcare Workers in Poland—Before and after BNT126b2 mRNA COVID-19 Vaccination

One of the groups most vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is healthcare workers (HCWs) who have direct contact with suspected and confirmed coronavirus diseases 2019 (COVID-19) patients. Therefore, this study aimed to (i) conduct a longitudinal analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorent, Dagny, Nowak, Rafał, Luwański, Dawid, Pisarska-Krawczyk, Magdalena, Figlerowicz, Magdalena, Zmora, Paweł
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607217/
https://www.ncbi.nlm.nih.gov/pubmed/36298441
http://dx.doi.org/10.3390/vaccines10101576
_version_ 1784818487453024256
author Lorent, Dagny
Nowak, Rafał
Luwański, Dawid
Pisarska-Krawczyk, Magdalena
Figlerowicz, Magdalena
Zmora, Paweł
author_facet Lorent, Dagny
Nowak, Rafał
Luwański, Dawid
Pisarska-Krawczyk, Magdalena
Figlerowicz, Magdalena
Zmora, Paweł
author_sort Lorent, Dagny
collection PubMed
description One of the groups most vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is healthcare workers (HCWs) who have direct contact with suspected and confirmed coronavirus diseases 2019 (COVID-19) patients. Therefore, this study aimed to (i) conduct a longitudinal analysis of the seroprevalence of SARS-CoV-2 infection among HCWs working in two healthcare units (HCUs) in Poland and (ii) identify anti-SARS-CoV-2 IgG antibody (Ab) response factors following infection and anti-COVID-19 vaccination. The overall seroprevalence increased from 0% at baseline in September 2020 to 37.8% in December 2020. It reached 100% in February 2021 after BNT126b2 (Pfizer New York, NY, USA/BioNTech Mainz, Germany) full vaccination and declined to 94.3% in September 2021. We observed significant differences in seroprevalence between the tested high- and low-risk infection HCUs, with the highest seropositivity among the midwives and nurses at the Gynecology and Obstetrics Ward, who usually have contact with non-infectious patients and may not have the proper training, practice and personal protective equipment to deal with pandemic infections, such as SARS-CoV-2. We also found that anti-SARS-CoV-2 Ab levels after coronavirus infection were correlated with disease outcomes. The lowest Ab levels were found among HCWs with asymptomatic coronavirus infections, and the highest were found among HCWs with severe COVID-19. Similarly, antibody response after vaccination depended on previous SARS-CoV-2 infection and its course: the highest anti-SARS-CoV-2 Ab levels were found in vaccinated HCWs after severe COVID-19. Finally, we observed an approximately 90–95% decrease in anti-SARS-CoV-2 Ab levels within seven months after vaccination. Our findings show that HCWs have the highest risk of SARS-CoV-2 infection, and due to antibody depletion, extra protective measures should be undertaken. In addition, in the context of the emergence of new pathogens with pandemic potential, our results highlight the necessity for better infectious disease training and regular updates for the low infection risk HCUs, where the HCWs have only occasional contact with infectious patients.
format Online
Article
Text
id pubmed-9607217
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96072172022-10-28 The Longitudinal Analysis on the Anti-SARS-CoV-2 Antibodies among Healthcare Workers in Poland—Before and after BNT126b2 mRNA COVID-19 Vaccination Lorent, Dagny Nowak, Rafał Luwański, Dawid Pisarska-Krawczyk, Magdalena Figlerowicz, Magdalena Zmora, Paweł Vaccines (Basel) Article One of the groups most vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is healthcare workers (HCWs) who have direct contact with suspected and confirmed coronavirus diseases 2019 (COVID-19) patients. Therefore, this study aimed to (i) conduct a longitudinal analysis of the seroprevalence of SARS-CoV-2 infection among HCWs working in two healthcare units (HCUs) in Poland and (ii) identify anti-SARS-CoV-2 IgG antibody (Ab) response factors following infection and anti-COVID-19 vaccination. The overall seroprevalence increased from 0% at baseline in September 2020 to 37.8% in December 2020. It reached 100% in February 2021 after BNT126b2 (Pfizer New York, NY, USA/BioNTech Mainz, Germany) full vaccination and declined to 94.3% in September 2021. We observed significant differences in seroprevalence between the tested high- and low-risk infection HCUs, with the highest seropositivity among the midwives and nurses at the Gynecology and Obstetrics Ward, who usually have contact with non-infectious patients and may not have the proper training, practice and personal protective equipment to deal with pandemic infections, such as SARS-CoV-2. We also found that anti-SARS-CoV-2 Ab levels after coronavirus infection were correlated with disease outcomes. The lowest Ab levels were found among HCWs with asymptomatic coronavirus infections, and the highest were found among HCWs with severe COVID-19. Similarly, antibody response after vaccination depended on previous SARS-CoV-2 infection and its course: the highest anti-SARS-CoV-2 Ab levels were found in vaccinated HCWs after severe COVID-19. Finally, we observed an approximately 90–95% decrease in anti-SARS-CoV-2 Ab levels within seven months after vaccination. Our findings show that HCWs have the highest risk of SARS-CoV-2 infection, and due to antibody depletion, extra protective measures should be undertaken. In addition, in the context of the emergence of new pathogens with pandemic potential, our results highlight the necessity for better infectious disease training and regular updates for the low infection risk HCUs, where the HCWs have only occasional contact with infectious patients. MDPI 2022-09-20 /pmc/articles/PMC9607217/ /pubmed/36298441 http://dx.doi.org/10.3390/vaccines10101576 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lorent, Dagny
Nowak, Rafał
Luwański, Dawid
Pisarska-Krawczyk, Magdalena
Figlerowicz, Magdalena
Zmora, Paweł
The Longitudinal Analysis on the Anti-SARS-CoV-2 Antibodies among Healthcare Workers in Poland—Before and after BNT126b2 mRNA COVID-19 Vaccination
title The Longitudinal Analysis on the Anti-SARS-CoV-2 Antibodies among Healthcare Workers in Poland—Before and after BNT126b2 mRNA COVID-19 Vaccination
title_full The Longitudinal Analysis on the Anti-SARS-CoV-2 Antibodies among Healthcare Workers in Poland—Before and after BNT126b2 mRNA COVID-19 Vaccination
title_fullStr The Longitudinal Analysis on the Anti-SARS-CoV-2 Antibodies among Healthcare Workers in Poland—Before and after BNT126b2 mRNA COVID-19 Vaccination
title_full_unstemmed The Longitudinal Analysis on the Anti-SARS-CoV-2 Antibodies among Healthcare Workers in Poland—Before and after BNT126b2 mRNA COVID-19 Vaccination
title_short The Longitudinal Analysis on the Anti-SARS-CoV-2 Antibodies among Healthcare Workers in Poland—Before and after BNT126b2 mRNA COVID-19 Vaccination
title_sort longitudinal analysis on the anti-sars-cov-2 antibodies among healthcare workers in poland—before and after bnt126b2 mrna covid-19 vaccination
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607217/
https://www.ncbi.nlm.nih.gov/pubmed/36298441
http://dx.doi.org/10.3390/vaccines10101576
work_keys_str_mv AT lorentdagny thelongitudinalanalysisontheantisarscov2antibodiesamonghealthcareworkersinpolandbeforeandafterbnt126b2mrnacovid19vaccination
AT nowakrafał thelongitudinalanalysisontheantisarscov2antibodiesamonghealthcareworkersinpolandbeforeandafterbnt126b2mrnacovid19vaccination
AT luwanskidawid thelongitudinalanalysisontheantisarscov2antibodiesamonghealthcareworkersinpolandbeforeandafterbnt126b2mrnacovid19vaccination
AT pisarskakrawczykmagdalena thelongitudinalanalysisontheantisarscov2antibodiesamonghealthcareworkersinpolandbeforeandafterbnt126b2mrnacovid19vaccination
AT figlerowiczmagdalena thelongitudinalanalysisontheantisarscov2antibodiesamonghealthcareworkersinpolandbeforeandafterbnt126b2mrnacovid19vaccination
AT zmorapaweł thelongitudinalanalysisontheantisarscov2antibodiesamonghealthcareworkersinpolandbeforeandafterbnt126b2mrnacovid19vaccination
AT lorentdagny longitudinalanalysisontheantisarscov2antibodiesamonghealthcareworkersinpolandbeforeandafterbnt126b2mrnacovid19vaccination
AT nowakrafał longitudinalanalysisontheantisarscov2antibodiesamonghealthcareworkersinpolandbeforeandafterbnt126b2mrnacovid19vaccination
AT luwanskidawid longitudinalanalysisontheantisarscov2antibodiesamonghealthcareworkersinpolandbeforeandafterbnt126b2mrnacovid19vaccination
AT pisarskakrawczykmagdalena longitudinalanalysisontheantisarscov2antibodiesamonghealthcareworkersinpolandbeforeandafterbnt126b2mrnacovid19vaccination
AT figlerowiczmagdalena longitudinalanalysisontheantisarscov2antibodiesamonghealthcareworkersinpolandbeforeandafterbnt126b2mrnacovid19vaccination
AT zmorapaweł longitudinalanalysisontheantisarscov2antibodiesamonghealthcareworkersinpolandbeforeandafterbnt126b2mrnacovid19vaccination